CO5031291A1 - Composicion farmaceutica - Google Patents
Composicion farmaceuticaInfo
- Publication number
- CO5031291A1 CO5031291A1 CO97052280A CO97052280A CO5031291A1 CO 5031291 A1 CO5031291 A1 CO 5031291A1 CO 97052280 A CO97052280 A CO 97052280A CO 97052280 A CO97052280 A CO 97052280A CO 5031291 A1 CO5031291 A1 CO 5031291A1
- Authority
- CO
- Colombia
- Prior art keywords
- controlled release
- dosage form
- oral
- pharmaceutical composition
- carboxymethylamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Una forma de dosificación oral de liberación controlada quecontiene el monohidrocloruro de [R-(Z)]-a-(metoxiimino)-a-(1-azabiciclo[2.2.2]oct-3-il) acetonitrilo(compuesto X), su base libre original o cualquier otra de sus sales farmacéuticamente aceptables.Una forma de dosificación de acuerdo con cualquiera de las reivindicaciones precedentes, que comprende una matriz hinchable y/o gelificable seleccionada entre alquilcelulosas, hidroxialquilcelulosas, poli(alcohol vinílico), polimetacrilatos, poli(metacrilatos de metilo), copolímeros de metacrilato/divinilbenceno, carboximetilamida, polioxialquilenglicoles, polivinilpirrolidona y carboximetilcelulosa.1Un método de tratamiento y/o profilaxis de la demencia, incluyendo la enfermedad de Alzheimer, en mamíferos, administrando una cantidad efectiva de una forma de dosificación oral de liberación controlada de acuerdo con la reivindicación 1, a un paciente que lo necesite.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5031291A1 true CO5031291A1 (es) | 2001-04-27 |
Family
ID=10799833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97052280A CO5031291A1 (es) | 1996-09-12 | 1997-09-09 | Composicion farmaceutica |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0929301A2 (es) |
JP (1) | JP2001500150A (es) |
KR (1) | KR20000036039A (es) |
CN (2) | CN1235544A (es) |
AR (1) | AR008176A1 (es) |
AU (1) | AU724086B2 (es) |
BR (1) | BR9711734A (es) |
CA (1) | CA2265661A1 (es) |
CO (1) | CO5031291A1 (es) |
CZ (1) | CZ83299A3 (es) |
GB (1) | GB9619074D0 (es) |
HU (1) | HUP9904401A3 (es) |
ID (1) | ID19589A (es) |
IL (1) | IL128781A0 (es) |
MA (1) | MA24359A1 (es) |
NO (1) | NO991194D0 (es) |
NZ (1) | NZ334268A (es) |
PE (1) | PE2499A1 (es) |
PL (1) | PL332074A1 (es) |
TR (1) | TR199900505T2 (es) |
WO (1) | WO1998010762A2 (es) |
ZA (1) | ZA978133B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
CA2323177A1 (en) * | 1998-03-11 | 1999-09-16 | Susan Marie Milosovich | Composition |
DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
KR101139744B1 (ko) * | 2003-04-25 | 2012-04-26 | 미쓰비시 타나베 파마 코퍼레이션 | 알킬렌 디옥시벤젠 유도체 함유 경구 투여용 조성물 |
DE602004002405T3 (de) * | 2003-05-14 | 2013-06-20 | Aptalis Pharma Limited | Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand |
US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
BRPI0513846A (pt) | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
CA2576386A1 (en) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0392803T3 (da) * | 1989-04-13 | 2004-10-18 | Beecham Group Plc | Hidtil ukendte forbindelser |
GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0929301A2 (en) | 1999-07-21 |
TR199900505T2 (es) | 1999-06-21 |
PE2499A1 (es) | 1999-03-24 |
KR20000036039A (ko) | 2000-06-26 |
BR9711734A (pt) | 1999-08-24 |
WO1998010762A2 (en) | 1998-03-19 |
WO1998010762A3 (en) | 1998-06-04 |
CA2265661A1 (en) | 1998-03-19 |
GB9619074D0 (en) | 1996-10-23 |
PL332074A1 (en) | 1999-08-30 |
CN1235544A (zh) | 1999-11-17 |
CN1446535A (zh) | 2003-10-08 |
NO991194L (no) | 1999-03-11 |
MA24359A1 (fr) | 1998-07-01 |
AR008176A1 (es) | 1999-12-09 |
NZ334268A (en) | 2000-10-27 |
ZA978133B (en) | 1999-04-12 |
AU4128897A (en) | 1998-04-02 |
NO991194D0 (no) | 1999-03-11 |
JP2001500150A (ja) | 2001-01-09 |
HUP9904401A3 (en) | 2001-03-28 |
HUP9904401A2 (hu) | 2000-06-28 |
IL128781A0 (en) | 2000-01-31 |
CZ83299A3 (cs) | 1999-08-11 |
ID19589A (id) | 1998-07-23 |
AU724086B2 (en) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO179250C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol | |
CO5031291A1 (es) | Composicion farmaceutica | |
MX9405219A (es) | Nueva formulacion farmaceutica. | |
CY1106072T1 (el) | Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος | |
AR064896A2 (es) | Composicion farmaceutica no higroscopica | |
LU91147I2 (fr) | Pemetrexed et ses sels pharmaceutiquement acceptables. | |
ES2180251T3 (es) | Comprimido revestido con polimero, que contiene amoxicilina y clavulanato. | |
DK372786D0 (da) | Farmaceutiske praeparater af phenindamin | |
MX9203278A (es) | Pastilla de liberacion sustentada que comprende loratadina, ibuprofen y pseudoefedrina. | |
GR1000465B (el) | Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιεχουν ακετυλ d-καρνιτινη για την θεραπευτικη αγωγη του γλαυκωματος. | |
ATE189400T1 (de) | Knochenwachstumsfördernde zusammensetzung | |
DK0503440T3 (da) | Sumatriptanholdige lægemidler | |
BR0009718A (pt) | Processo de tratamento | |
RU2000131897A (ru) | Пероральная дозировочная композиция пролонгированного действия | |
NL980008I1 (nl) | Gebruik van sertindool voor de behandeling van schizofrenie. | |
ATE133563T1 (de) | Pharmazeutische lutschpastillen | |
AR026968A1 (es) | Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral | |
BR0013935A (pt) | IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos | |
HUP0004282A2 (hu) | 2-Halogén-6-0-szubsztituált ketolidszármazékok | |
NO178338C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt | |
EP0670166A3 (en) | Pharmaceutical compositions for oral administration. | |
AR002191A1 (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion | |
DE69012031D1 (de) | Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung. | |
LU90110I2 (fr) | Penciclovir et ses dérivés pharmaceutiquement acceptables | |
NO993921D0 (no) | Medikament mot infertilitet og for ökt fertilitet |